By Drug Target Review2024-06-04T12:30:07
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-30T09:54:00Z
2026-03-26T13:58:00Z
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2023-02-23T14:02:18
Sponsored by bit.bio
2023-04-12T15:28:08
Sponsored by nanoComposix
2023-03-20T13:41:33
Sponsored by Bio-Techne
2024-01-19T07:40:55
Sponsored by Euretos
Site powered by Webvision Cloud